Why Krystal Biotech’s latest earnings are moving the stock

Krystal Biotech (KRYS) is back on investors’ radar after Q1 2026 earnings topped expectations, with Vyjuvek-driven revenue and recent FDA approval updates drawing fresh attention to the stock’s risk reward profile.

Beyond the earnings beat, Krystal Biotech’s share price has picked up momentum, with a 7 day share price return of 13.13% and a year to date share price return of 20.17%, while the 1 year total shareholder return of 116.30% and 5 year total shareholder return of 374.42% point to strong longer term gains.

If strong biotech momentum has your attention, this could be a good moment to look across the sector and see which other companies are breaking out via 35 healthcare AI stocks

With Krystal Biotech trading at $296.70 compared to an average analyst price target of $318.22 and an intrinsic value estimate that implies a large discount, the key question is whether there is still potential upside or if the market has already fully priced in future growth.

Most Popular Narrative: 5.8% Undervalued

Krystal Biotech’s most followed narrative pegs fair value at $315 per share, slightly above the last close at $296.70, framing the recent move as only part of the story.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product. Favorable dynamics in global healthcare, such as greater willingness to reimburse curative, high-value genetic therapies and broadening awareness due to successful launches and patient outcomes, should support sustainable long-term revenue growth and premium pricing, boosting revenue visibility and potentially net margins.

Want to see what sits behind that $315 fair value? The narrative leans on ambitious growth, rising margins, and a richer earnings mix. The exact assumptions might surprise you.

Using a 7.14% discount rate, the narrative connects higher long term earnings forecasts, improving net margins and a lower future P/E multiple to justify that $315 figure, which is close to the current analyst consensus target of $315 and only modestly above the latest close.

Result: Fair Value of $315 (UNDERVALUED)

However, this hinges on Vyjuvek remaining on track and on Krystal securing favorable reimbursement abroad, where delays or pricing pressure could quickly undercut those fair value assumptions.

Another Way To Look At The Valuation

The narrative and analyst target lean on earnings forecasts and a future P/E of about 20x, but the current P/E near 38.9x tells a very different story. That is much higher than the US Biotechs industry at 17.8x and above a fair ratio of 21.3x, which points to meaningful valuation risk if sentiment cools.

Before you lean too heavily on one framework, it is worth asking which outcome you think is more realistic if growth, margins, or sentiment shift from today’s assumptions, and whether that gap sits comfortably with your risk tolerance. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Confident in the story so far, or still on the fence about where the real opportunity lies here? Act while sentiment is focused and weigh up the company's 3 key rewards

Looking for more investment ideas?

If Krystal Biotech has sharpened your focus, do not stop here. Widening your watchlist now can help you spot opportunities before they become crowded.

• Target higher quality at better prices by scanning 51 high quality undervalued stocks that pair solid fundamentals with appealing valuations.
• Strengthen your income stream by reviewing 12 dividend fortresses that combine sizeable yields with an emphasis on resilience.
• Prioritise peace of mind by checking 72 resilient stocks with low risk scores designed to highlight companies with lower risk profiles and steadier characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.